Novonesis delivers 8% organic sales growth with an adjusted EBITDA margin of 36.1% in 2024. For 2025, Novonesis presents an outlook of 5-8% organic sales growth with an adjusted EBITDA margin of 37-38%.
12M 2024: Novonesis delivers strong full-year results and expects continued growth in 2025
Seeking Alpha / 7 minutes from now 2 Views
Comments